Gilliland Named President and Director of Fred Hutchinson Cancer Research Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

D. GARY GILLILAND was named president and director of the Fred Hutchinson Cancer Research Center, effective Jan. 2, 2015.

Gilliland comes from the University of Pennsylvania’s Perelman School of Medicine, where he served as vice president of precision medicine. Previously, he was an executive at Merck Research Laboratories, a professor of medicine for more than 20 years at Harvard Medical School, and a Howard Hughes Medical Institute investigator.

He directed the leukemia program at Dana-Farber/Harvard Cancer Center, and was also a professor of stem cell and regenerative biology.His research has focused on the genetic basis of blood cancers.

He will become the fifth president and director of Fred Hutch, taking over for Mark Groudine, the acting president and director. He is preceded by Lawrence Corey, Nobel laureate Lee Hartwell, Robert Day, and founder William Hutchinson.

According to the center, Gilliland is hopeful that immunotherapy can be successfully applied against a host of diseases that are caused by viruses, from hepatitis C to Burkitt lymphoma and other infectious disease-related cancers, which account for about a quarter of all malignancies worldwide.He also wants to focus on the development of targeted cancer therapies, working with the University of Washington.

Gilliland has received the William Dameshek Prize from the American Society of Hematology, the Emil J. Freireich Award from the MD Anderson Cancer Center, and the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation, of which he is an elected member. He is also an elected member of the American Association of Physicians.

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login